Tourmaline Bio (NASDAQ:TRML - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Tourmaline Bio to post earnings of ($0.91) per share for the quarter.
Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Tourmaline Bio Price Performance
NASDAQ:TRML traded down $0.65 during mid-day trading on Friday, reaching $15.09. The stock had a trading volume of 287,554 shares, compared to its average volume of 271,269. The company has a market capitalization of $387.59 million, a price-to-earnings ratio of -5.35 and a beta of 2.11. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The stock's 50 day simple moving average is $15.49 and its two-hundred day simple moving average is $18.78.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on TRML shares. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a report on Monday, May 5th. Chardan Capital reiterated a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Wedbush raised their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. Finally, Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio currently has an average rating of "Buy" and a consensus price target of $49.33.
Read Our Latest Stock Analysis on Tourmaline Bio
About Tourmaline Bio
(
Get Free Report)
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Featured Articles

Before you consider Tourmaline Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.
While Tourmaline Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.